Sanofi-Aventis and Novozymes have signed a development and marketing collaboration for a potential new antibiotic. The drug candidate is an antimicrobial peptide named Plectasin NZ2114 that targets the treatment of severe infections, such as pneumonia and septicaemia, caused by bacteria like Staphylococcus and Streptococcus. SA has been granted an exclusive worldwide license for the development, registration and commercialization of the drug. The two companies will  work to develop and implem...